Open AccessExpert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach
Author(s) -
Raymond S. Douglas,
Andrea L. Kossler,
Jody Abrams,
César A. Briceño,
David Gay,
Andrew R. Harrison,
Michael Lee,
John Nguyen,
Shan S. Joseph,
Dianne Schlachter,
Jeremy Tan,
Judah Lynch,
Louisa Oliver,
Richard Perry,
Shoaib Ugradar
Publication year - 2022
Publication title -
journal of neuro-ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.586
H-Index - 55
eISSN - 1536-5166
pISSN - 1070-8022
DOI - 10.1097/wno.0000000000001560
Subject(s) - medicine , delphi method , concomitant , adverse effect , family medicine , quality of life (healthcare) , delphi , food and drug administration , optic neuropathy , likert scale , physical therapy , psychology , medical emergency , ophthalmology , nursing , developmental psychology , statistics , mathematics , computer science , operating system , optic nerve
Teprotumumab is the first treatment for thyroid eye disease (TED), a debilitating autoinflammatory condition, approved by the Food and Drug Administration in the United States, which reduces proptosis and improves quality of life. In the absence of guidelines, clinical recommendations were developed for using teprotumumab in patients with TED in the United States.